PARADIGM BIOPHARMACEUTICALS

They focus on repurposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. They address conditions that start with and are sustained by inflammation. Lead clinical indications involve treating injury that results in bone marrow edema (BME) and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’.